TABLE 7.
Steady-state plasma amprenavir and ritonavir pharmacokinetic treatment comparisonsa
| Parameter | APV treatment comparisonsb
|
RTV treatment comparisons
|
||||
|---|---|---|---|---|---|---|
| B/A | C/A | C/B | B/A | C/A | C/B | |
| AUC(0-τ) (μg · h/ml) | 1.54 (1.31-1.81) | 1.26 (1.07-1.48) | 0.818 (0.694-0.963) | 1.49 (0.980-2.25) | 4.15 (2.74-6.30) | 2.79 (1.84-4.24) |
| Cmax (μg/ml) | 1.81 (1.50-2.19) | 1.48 (1.22-1.78) | 0.817 (0.677-0.986) | 1.71 (1.06-2.75) | 4.17 (2.60-6.70) | 2.44 (1.52-3.92) |
| Cτ (μg/ml) | 1.26 (1.00-1.59) | 1.32 (1.05-1.66) | 1.04 (0.828-1.31) | 0.889 (0.549-1.44) | 3.99 (2.47-6.47) | 4.49 (2.77-7.27) |
a
Results are shown as geometric least squares mean ratio (90% CI).
b
Treatment A was FPV 700 mg BID plus RTV 100 mg BID, treatment B was FPV 1,400 mg BID plus RTV 100 mg BID, and treatment C was FPV 1,400 mg BID plus RTV 200 mg BID.